Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$766.30K$766.30Kderived+18.1% vs Q4 2024 Net Income-$579.08K-$579.08KderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$623,027N/M Operating Cash Flowderived-$242,682N/M Margins · derivedOperating margin-81.3%+88.1 pt vs Q4 2024
Net margin-75.6%+87.0 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end